Biogen
NEWS
One week after Johnna Rossell departed Biogen for Enzyvant, Biogen announced two more members of its board are leaving.
Clinical trial news definitely picked up this final week of January. Here’s a look.
Biogen is selling its nearly 50% stake in Samsung Bioepis for $2.3 billion. The move will provide Biogen with additional capital while preparing to cut additional costs through a rumored employee layoff.
Biogen and its partner Eisai Company released additional details about the Phase IV post-marketing study of the drug.
After guiding the commercial rollout of embattled Alzheimer’s drug Aduhelm for Biogen, Johanna Rossell has departed the company for a leadership role at Enzyvant.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
The Centers for Medicare and Medicaid Services indicated it would cover the cost of these drugs and any necessary scans — but only “if they are enrolled in qualifying clinical trials.”
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
Another drug Vounatsos heralded was zuranolone, which Biogen is developing with Sage Therapeutics for multiple forms of depression.
JOBS
IN THE PRESS